Gelteq is an early-stage Australian company that develops and commercializes edible gel-based delivery systems for health products. The core technology is a proprietary gel formulation that can encapsulate nutrients, supplements, or pharmaceutical ingredients into a single gel dosage form, designed to mask unpleasant tastes, control nutrient or drug release rates, and ease ingestion for people or animals who struggle to swallow pills. Gelteq's primary business model is white-label licensing: Gelteq develops formulations, manufactures through third-party contract manufacturers, and licenses them to companies who rebrand and sell the products under their own names. Licensees pay per-unit manufacturing costs, licensing fees, and royalties. Gelteq operates across five verticals — sports nutrition, nutraceuticals, pet health, OTC, and prescription pharma — prioritized roughly by speed to market. The near-term focus is sports and nutraceuticals, where food-grade ingredients require no regulatory approval. Pet health supplements are formulated and ready for scale-up. The longer-term, higher-value opportunity is pharmaceutical, where Gelteq is pursuing FDA approval via the 505(b)(2) pathway for an OTC pain management gel, and has an approved FDA suitability petition to pursue an animal drug application. Gelteq's IP position rests on two granted patent families, five additional provisional applications, and a research partnership with Monash University. The company is still early-stage, with very limited revenue, and is funded primarily through its 2024 IPO proceeds and an equity line of credit.